Max Rosett
About Max Rosett
Max Rosett is Immunome’s Chief Financial Officer (CFO) and Principal Financial and Accounting Officer, serving as CFO since May 2024 after stints as Interim CFO and EVP Operations (Jan–May 2024) and SVP Operations (Oct 2023–Jan 2024) . He is 35 years old, holds an M.S. in Computer Science (Georgia Tech) and a B.A. in Mathematics (Yale), and previously worked as an engineer at Google and began his career at Boston Consulting Group serving pharma clients . During his tenure, Immunome remained pre-commercial with collaboration revenue and continued R&D investment; recent quarters show modest revenue and negative EBITDA as the company advanced AL102 and ADC/RLT programs .
Company performance during Rosett’s tenure (last four quarters):
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue ($USD) | $2,738,000* | $2,926,000* | $4,015,000* | N/A* |
| EBITDA ($USD) | $(55,148,000)* | $(44,025,000)* | $(45,841,000)* | $(59,549,000)* |
Values retrieved from S&P Global.
Note: Company disclosures indicate collaboration revenue and ongoing losses as R&D scales .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Immunome | CFO | May 2024–present | Principal Financial & Accounting Officer; signed 2024 Form 10-K certifications . |
| Immunome | EVP Operations & Interim CFO | Jan 2024–May 2024 | Appointed principal accounting officer after Controller’s resignation . |
| Immunome | SVP Operations | Oct 2023–Jan 2024 | Post-merger operational leadership . |
| Morphimmune | Acting COO | Mar 2022–Oct 2023 | Led operations prior to merger closing . |
| Morphimmune | VP Portfolio Planning & Corporate Strategy | Jan 2022–Mar 2022 | Portfolio planning and strategy . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Research Bridge Partners | Principal | Mar 2021–Nov 2023 | Life sciences investing; led RBP’s Morphimmune Series A investment . |
| Research Bridge Partners | Director of Data Science | Feb 2018–Feb 2021 | Built data capabilities for life sciences investments . |
| Engineer | Not disclosed | Technical experience relevant to IT/cyber oversight . | |
| Boston Consulting Group | Consultant (Pharma) | Early career | Industry-facing strategy experience . |
Fixed Compensation
| Component | Amount | Effective Date | Source |
|---|---|---|---|
| Base Salary | $390,000 | Nov 1, 2023 (SVP Operations) | |
| Base Salary | $425,000 | Jan 31, 2024 (EVP Ops & Interim CFO) | |
| Target Bonus % | 30% of base salary | As of Nov 30, 2023 offer letter | |
| Relocation Payment | $100,000 (cash) | Jan 21, 2025 acceptance; payable within 10 days | |
| Housing Bonus | $300,000 (cash) upon purchase agreement for primary residence | Payable within 15 business days of notification; pro‑rata repayment over 3 years unless resignation for good reason/termination without cause or Bothell lab winddown clause triggered |
- 401(k) plan: Company matches 100% up to 3% of eligible compensation; broad-based plan available to executives and employees .
Performance Compensation
| Award Type | Grant Date | Shares/Units | Exercise Price | Vesting | Notes |
|---|---|---|---|---|---|
| Stock Option | Jan 31, 2024 | 175,000 | $16.57 | 25% at 1-year anniversary of grant; remaining 75% in 36 equal monthly installments thereafter (service-based) | Granted upon promotion to EVP Ops & Interim CFO under 2020 Plan . |
- Company practice: Executives typically receive time-vested stock options (initial grants with 1-year cliff then monthly; follow-on grants monthly over 4 years), with a 10-year term and exercise price at grant-date fair market value .
Equity Ownership & Alignment
| Holder | Common Shares Owned | Options Exercisable within 60 Days | Total Beneficial Ownership | Ownership % of Outstanding |
|---|---|---|---|---|
| Max Rosett | 47,476 | 149,140 | 196,616 | ~0.23% (196,616 / 86,796,919) |
- Anti-hedging/pledging: Company’s Insider Trading Policy prohibits hedging transactions, margin purchases, borrowing against company stock, or pledging company shares as collateral .
- ESPP: Executives are eligible to participate; purchases at 85% of lower of first-day or purchase-date price subject to plan limits .
- Stock ownership guidelines: Not disclosed for executives in available materials.
Employment Terms
| Provision | Baseline Severance (No CIC) | Change-in-Control Severance (Single/Double Trigger) | Notes |
|---|---|---|---|
| Base Salary Continuation | 12 months of base salary continuation | 12 months of base salary continuation | Employment Offer Terms (Nov 30, 2023). |
| Bonus | Pro‑rated annual bonus for year of termination based on achievement | Full annual bonus amount for year of termination | Lump-sum timing post-separation (60 days) . |
| COBRA | Up to 12 months of employer‑paid COBRA or taxable equivalent | Up to 12 months of employer‑paid COBRA or taxable equivalent | Special Severance Payment if direct payment would incur penalties . |
| Equity | — | 100% acceleration of all unvested equity awards upon CIC termination window (30 days prior to, at, or within 12 months post-CIC) | Double-trigger formulation; requires separation for good reason or without cause . |
| Conditions | Return of company property; separation agreement and general release; 60-day window for effectiveness | Same conditions | Definitions of Good Reason/Cause per Offer Letter . |
Relocation package retention mechanics:
- $100,000 Relocation Payment must be repaid if relocation not completed by Jan 21, 2026 or if Rosett does not remain employed for 90 days after relocation, except if resignation for good reason or termination without cause .
- $300,000 Housing Bonus pro‑rata repayment over three years if terminated for cause or resigns without good reason; repayment waived if Bothell lab headcount drops below 10 before end of the three-year period .
Employment, Governance, and Cyber Oversight
- CFO certifications: Rosett signed Section 302 and 906 SOX certifications for FY2024 Form 10-K .
- Cybersecurity governance: CFO co-leads cybersecurity risk assessment and incident response with Head of IT; responsible for budgets, process approvals, and reporting to the Audit Committee .
Investment Implications
- Retention and alignment: Material service-based option grant (175,000) and relocation/housing incentives create retention “handcuffs,” while the anti-hedging/pledging policy strengthens alignment with long-term shareholders .
- Potential selling pressure in a CIC: 100% equity acceleration under a CIC separation could increase liquidity overhang if a transaction occurs; however, acceleration is conditioned on a separation within the specified window (double trigger) .
- Execution risk: Immunome remains pre-commercial and loss-making; CFO’s role includes financing and controls as the company executed an upsized public offering in Jan 2025 ($161.7M net proceeds) and ATM sales ($64.5M net through Sept 30, 2025), supporting multi-year R&D runway amid continued negative EBITDA .
- Performance-based pay visibility: Specific CFO bonus metrics were not disclosed; company-wide goals for NEOs included research/development/corporate objectives with non-equity bonuses tied to goal achievement, but CFO was not a 2024 NEO—limiting pay-for-performance transparency for this role .
Overall: Rosett’s compensation is primarily equity/time-based with robust severance/CIC protection and meaningful relocation retention incentives. This structure emphasizes retention and long-term value creation but could concentrate payout and equity acceleration in a CIC scenario. The anti-pledging policy mitigates alignment concerns, and cybersecurity oversight adds operational breadth in his remit .